文献速递产科母胎医学

宽松产时血糖控制:一项等效性随机对照试验(PERMIT)

Permissive intrapartum glucose control: an equivalence randomized control trial (PERMIT).
PubMed 文献 · Am J Obstet Gynecol · 2024-06-12

这项在两家中心开展的等效性随机对照试验纳入≥34周分娩的糖尿病个体,比较宽松管理(目标血糖70-180 mg/dL)与常规管理(血糖70-110 mg/dL)。常规管理组17%需要胰岛素滴注而宽松组无需,主要结局新生儿首次足跟血糖两组等效(57.9 vs 57.1 mg/dL),贝叶斯分析显示均值差不超过10 mg/dL的后验概率为98%。

要点

  • 宽松产时血糖目标(70-180 mg/dL)与常规目标(70-110 mg/dL)的新生儿首次血糖等效。
  • 常规管理组17%需要胰岛素滴注,宽松管理组无一人需要。
  • 新生儿低血糖率常规组25% vs 宽松组29%,校正相对风险1.14(95%CI 0.60-2.17)。

核心结论

  • 在糖尿病个体中,常规产时血糖管理下近六分之一需要胰岛素滴注,而宽松管理与等效的新生儿血糖相关。

研究设计与样本

  • 两中心等效性随机对照试验,纳入≥34周分娩的孕前或妊娠期糖尿病个体,随机分配至常规管理或宽松管理。
  • 潜伏期和活跃期分别每4小时和每2小时监测毛细血管血糖,超过所分配目标上限时启动胰岛素滴注。
  • 主要结局为出生后2小时内喂养前首次新生儿足跟血糖;假设均值50±10 mg/dL,为检测均值差不超过10 mg/dL(双侧a=0.05,b=0.1)需96例。
  • 共评估511例糖尿病分娩,280例(54.8%)符合标准,96例(34.3%)同意并随机化。
  • 采用意向性分析计算校正相对风险和95%置信区间,并用预设贝叶斯分析以中性信息先验估计等效概率。

主要发现

  • 常规管理组17%需要胰岛素滴注,宽松管理组为0。
  • 主要结局两组等效:常规管理组57.9 mg/dL vs 宽松管理组57.1 mg/dL,校正均值差-0.72(95%CI -8.87至7.43)。
  • 贝叶斯分析显示均值差不超过10 mg/dL的后验概率为98%。
  • 新生儿低血糖率常规管理组25% vs 宽松管理组29%,校正相对风险1.14(95%CI 0.60-2.17)。
  • 其他新生儿或母体结局无差异。

关键数值与推荐

  • 常规管理目标血糖70-110 mg/dL,宽松管理目标血糖70-180 mg/dL。
  • 潜伏期每4小时、活跃期每2小时监测毛细血管血糖,超过目标上限启动胰岛素滴注。
  • 主要结局为出生后2小时内喂养前首次新生儿足跟血糖。
  • 等效界值为新生儿首次血糖均值差不超过10 mg/dL。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is limited high-quality data on the best practices for maternal blood glucose management during labor. OBJECTIVE: We compared permissive care (target maternal blood glucose 70-180 mg/dL) to usual care (blood glucose 70-110 mg/dL) among laboring individuals with diabetes. STUDY DESIGN: This was a two-site equivalence randomized control trial for individuals with diabetes (pregestational or gestational) at ≥34 weeks in labor. Individuals were randomly allocated to usual care or permissive care. Maternal blood glucose was evaluated by capillary blood glucose monitoring in latent and active labor every 4 and 2 hours. Insulin drip was initiated if maternal blood glucose exceeded the upper bounds of the allocated target. The primary outcome was the first neonatal heel stick glucose within 2 hours of birth before feeding. We assumed a mean first neonatal blood glucose of 50±10 mg/dL. To ensure that the use of permissive care did not increase or decrease the first neonatal blood glucose >10 mg/dL (2-tailed: a=0.05, b=0.1), 96 total participants were required. We calculated adjusted relative risk and 95% confidence intervals in an intention-to-treat analysis. A preplanned Bayesian analysis was used to estimate the probability of equivalence with a neutral informative prior. RESULTS: Of deliveries with diabetes assessed for eligibility (from October 2022 to June 2023), 280 of 511 (54.8%) met eligibility criteria, and 96 of 280 (34.3%) agreed and were randomized. In the usual care group, 17% required an insulin drip compared with none in permissive care. There was equivalence in the primary outcome between usual and permissive care (57.9 vs 57.1 mg/dL; adjusted mean difference, -0.72 [95% confidence interval, -8.87 to 7.43]). Bayesian analysis indicated a 98% posterior probability of the mean difference not being >10 mg/dL. The rate of neonatal hypoglycemia was 25% in the usual care group and 29% in the permissive group (adjusted relative risk, 1.14; 95% confidence interval, 0.60-2.17). There was no difference in other neonatal or maternal outcomes. CONCLUSION: In this randomized control trial, although almost 1 in 6 individuals with diabetes required an insulin drip with usual intrapartum maternal blood glucose care, permissive care was associated with equivalent neonatal blood glucose.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Bitar G, Bravo R, Pedroza C, et al. Permissive intrapartum glucose control: an equivalence randomized control trial (PERMIT). Am J Obstet Gynecol. 2024. PMID: 38876413. doi:10.1016/j.ajog.2024.05.053

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。